Refractory disease at end-of-induction (no CR/PR after 4 cycles CHOEP) OR rapid relapse —...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-EATL-TRANSFORMATION-PROGRESSION`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-EATL`
Sources	`SRC-ESMO-PTCL-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	Refractory disease at end-of-induction (no CR/PR after 4 cycles CHOEP) OR rapid relapse — alloSCT or experimental therapy (brentuximab if CD30+, romidepsin/HDAC-i salvage).
Clinical direction	investigate
Category	transformation-progression

Trigger Logic

{
  "any_of": [
    {
      "finding": "eatl_no_response_after_4_cycles",
      "value": true
    },
    {
      "finding": "eatl_rapid_relapse",
      "value": true
    }
  ],
  "type": "composite_clinical"
}

Notes

Refractory EATL has dismal prognosis; clinical trial referral is the recommended next step.

Used By

No reverse references found in the YAML corpus.